Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.

Autor: Tsampalieros A; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada., Zemek R; Department of Pediatrics and Emergency Medicine, Children's Hospital of Eastern Omntario, University of Ottawa, Ottawa, Canada., Barrowman N; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada., Langlois MA; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada., Arnold C; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada., McGahern C; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada., Plint AC; Department of Pediatrics and Emergency Medicine, Children's Hospital of Eastern Omntario, University of Ottawa, Ottawa, Canada., Pham-Huy A; Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada., Bhatt M; Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada. Electronic address: mbhatt@cheo.on.ca.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Aug 13; Vol. 42 (20), pp. 125981. Date of Electronic Publication: 2024 May 23.
DOI: 10.1016/j.vaccine.2024.05.029
Abstrakt: Background: The immune response to coronavirus disease 2019 (COVID-19) vaccination is stronger among adults with prior infection (hybrid immunity). It is important to understand if children demonstrate a similar response to better inform vaccination strategies. Our study investigated the humoral response after BNT162b2 COVID-19 vaccine doses in SARS-CoV-2 naïve and recovered children (5-11 years).
Methods: A multi-institutional, longitudinal, prospective cohort study was conducted. Children were enrolled in a case-ascertained antibody surveillance study in Ottawa, Ontario from September/2020-March/2021; at least one household member was severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive on RT-PCR. In November 2021, BNT162b2 COVID-19 vaccine was authorized for children aged 5-11 in Canada. Children enrolled in the surveillance study intending to receive two vaccine doses were invited to participate in this study from November 2021-April 2022. Main exposure was prior SARS-CoV-2 infection, defined by positive RT-PCR or SARS-CoV-2 anti-N IgG antibody presence. Primary outcome was spike IgG antibody levels measured following the first vaccine dose (2-3 weeks) and second vaccine dose (3-4 weeks).
Results: Of the 153 eligible children, 75 participants (median age 8.9 IQR (7.4, 10.2) years; 38 (50.7 %) female; 59 (78.7 %) Caucasian) had complete follow-up. Fifty-four (72 %) children had prior SARS-COV-2 infection. Spike IgG antibody levels are significantly higher in SARS-CoV-2 recovered participants after receiving the first dose (p < 0.001) and the second (p = 0.01) compared to infection naïve children.
Conclusions and Relevance: SARS-CoV-2 recovered children (5-11 years) demonstrated higher antibody levels following first BNT162b2 vaccine dose compared with naïve children. Most reached antibody saturation two to three weeks after the first dose; a second dose didn't change the saturation level. A single vaccine dose in SARS-CoV-2 recovered children may be equivalent or superior to a 2-dose primary series in naïve children. Further research is needed on the durability and quality of a single vaccine dose in this population.
Competing Interests: Declaration of competing interest AP reports a relationship with Member of the Task Force for COVID-19 in Children, Government of Canada (no financial compensation) that includes: non-financial support. RZ is supported by a Tier 1 Clinical Research Chair from University of Ottawa.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: